Details for New Drug Application (NDA): 218364
✉ Email this page to a colleague
NDA 218364 describes LEVETIRACETAM IN SODIUM CHLORIDE, which is a drug marketed by B Braun Medical, Baxter Hlthcare Corp, Caplin, Eugia Pharma, Fresenius Kabi Usa, Gland, Hikma, Hq Spclt Pharma, Mylan Labs Ltd, and Nexus, and is included in ten NDAs. It is available from fourteen suppliers. Additional details are available on the LEVETIRACETAM IN SODIUM CHLORIDE profile page.
The generic ingredient in LEVETIRACETAM IN SODIUM CHLORIDE is levetiracetam. There are thirty-five drug master file entries for this compound. Eighty-eight suppliers are listed for this compound. Additional details are available on the levetiracetam profile page.
The generic ingredient in LEVETIRACETAM IN SODIUM CHLORIDE is levetiracetam. There are thirty-five drug master file entries for this compound. Eighty-eight suppliers are listed for this compound. Additional details are available on the levetiracetam profile page.
Summary for 218364
| Tradename: | LEVETIRACETAM IN SODIUM CHLORIDE |
| Applicant: | Mylan Labs Ltd |
| Ingredient: | levetiracetam |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INTRAVENOUS | Strength | 500MG/100ML (5MG/ML) | ||||
| Approval Date: | May 8, 2026 | TE: | AP | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INTRAVENOUS | Strength | 1GM/100ML (10MG/ML) | ||||
| Approval Date: | May 8, 2026 | TE: | AP | RLD: | No | ||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INTRAVENOUS | Strength | 1.5GM/100ML (15MG/ML) | ||||
| Approval Date: | May 8, 2026 | TE: | AP | RLD: | No | ||||
Complete Access Available with Subscription
